mCRPC
Metastatic castration-resistant prostate cancer
Advertisement
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice.
Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3.
Neeraj Agarwal, MD, highlights the significance of TALAPRO-2 in mCRPC and the data for rPFS with respect to HRR status.
A new study examined the relationship between pathogenic germline BRCA2 mutation and somatic change in circulating tumor DNA.
A study reviewed the prognostic value of neuroendocrine differentiation in mCRPC patients receiving abiraterone or docetaxel.
Dr. Tanya Dorff highlights the mCRPC treatment approaches worth monitoring, including sequential and combination strategies.
Tanya Dorff, MD, provides an overview of the latest data for PARP inhibitor plus AR-targeted agents for patients with mCRPC.
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
A study compared the gross and OOP payments for 6 different first-line mCRPC drugs during the 6 months post-treatment start.
Medicare beneficiaries with metastatic prostate cancer incurred additional average costs of over $30,000 annually.
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
A new study examined the efficacy of abiraterone, enzalutamide, and docetaxel in patients with BRCA-positive mCRPC.
Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety.
Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients.
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Studies have investigated the effects of 177Lu-PSMA and 225Ac-PSMA RNT in mCRPC patients, with promising treatment results.
Olaparib with cediranib significantly improved rPFS in men with mCRPC, but was associated with an increase in adverse events.
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
Advertisement
670 Madison Ave.
Manalapan, NJ 07726